

Confirmed Speakers

Plenary Speakers

PL09 - Paul Ehrlich Award Lecture - Chemical Biology on the Genome



Prof. Sir Shankar BALASUBRAMANIAN
(UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom)

PL17 - Nanoparticle-based Strategies in Oncology



Prof. Jean-Pierre BENOIT
(UNIVERSITY OF ANGERS, Angers, France)

PL22 - Two Adventures in Chemical Biology - in vivo Chemistry and Real-time Optical Medical Imaging



Prof. Mark BRADLEY
(UNIVERSITY OF EDINBURGH, Edinburgh, United Kingdom)

PL01 - Disrupting Cancer Care & Outcomes by Putting Patients in the Driving Seat



Dr Anne BRUINVELS
(PX HEALTHCARE, London, United Kingdom)

PL21 - Pierre Fabre Award lecture PROTAC-mediated Protein Degradation: A New Therapeutic Modality



Prof. Craig CREWS
(UNIVERSITY OF YALE, New Haven, United States)

PL04 - Ghrelin Receptor Ligands: from the Bench to the Drug on the Market



Dr Jean-Alain FEHRENTZ
(CNRS-UNIVERSITY OF MONTPELLIER, Montpellier, France)

PL11 - Identification of Chemokine Neutraligands Targeting Atopic Diseases and Hyperalgesia



Dr Jean-Luc GALZI
(CNRS-UNIVERSITY OF STRASBOURG, Illkirch, France)

PL10 - Ancient and Modern Scaffolds for Biologically Active Chemical Space



Prof. Arasu GANESAN
(UNIVERSITY OF EAST ANGLIA, Norwich, United Kingdom)

PL06 - Structure-guided Development of Selective GPCR Ligands

Confirmed Speakers



Prof. Peter GMEINER
(FRIEDRICH ALEXANDER UNIVERSITY, Erlangen, Germany)

PL07 - Late Stage Fluorination for Medicine



Prof. Véronique GOUVERNEUR
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

PL15 - Identifying Inter-Helical Interactions Involved in GPCR Structure-Function and the Forces that Determine Receptor-Ligand Residence Time



Dr Alexander HEIFETZ
(EVOTEC, Abingdon, United Kingdom)

PL05 - Structure-Based Drug Discovery for G Protein-Coupled Purine Receptors



Prof. Kenneth A. JACOBSON
(NIDDK, Bethesda, United States)

PL19 - Chemical Tools to Probe Reversible Lysine Acetylation



Prof. Manfred JUNG
(ALBERT LUDWIGS UNIVERSITY OF FREIBURG, Freiburg, Germany)

PL14 - Pharmacophore-based Analysis of Molecular Dynamics Trajectories: Towards Understanding KD of Protein Ligands



Prof. Thierry LANGER
(UNIVERSITY OF VIENNA, Vienna, Austria)

PL13 - Potential Therapeutic Targets in the Brain Renin-Angiotensin and Apelinergic Systems for Treatment of Cardiovascular Diseases



Dr Catherine LLORENS-CORTES
(INSERM/COLLÈGE DE FRANCE, Paris, France)

PL18 - Chemistry as the Helping Tool to Develop New Therapeutic Strategies



Prof. Maria Luz LOPEZ RODRIGUEZ
(COMPLUTENSE UNIVERSITY OF MADRID, Madrid, Spain)

PL20 - The Confobody Technology, a New Platform to Enable Fragment Screening on GPCRs



Dr Christel MENET
(CONFO THERAPEUTICS, Brussels, Belgium)

Confirmed Speakers

PL02 - Chemogenetic Approaches to Validate Poorly Characterised GPCRS



Prof. Graeme MILLIGAN
(UNIVERSITY OF GLASGOW, Glasgow, United Kingdom)

PL08 - Single Electron Processes Enabling Organic Synthesis



Prof. Gary A. MOLANDER
(UNIVERSITY OF PENNSYLVANIA, Philadelphia, United States)

PL12 - Discovery of Foliglurax, an mGluR4 PAM for the Treatment of Parkinson's Disease



Dr Stephan SCHANN
(DOMAIN THERAPEUTICS SA, Illkirch, France)

PL03 - Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism



Dr Patrick SCHNIDER
(ROCHE PHARMACEUTICAL, Schlieren, Switzerland)

PL23 - Therapeutic In Vivo Synthetic Chemistry



Prof. Nori TANAKA
(RIKEN, Saitama, Japan)

PL16 - Cellular Delivery and Oral Uptake of Cyclic Peptides



Dr Thomas VORHERR
(NOVARTIS, Basel, Switzerland)

Keynote Speakers

KL05 - Topical Intestinal Agonists of the Bile Acid Receptor TGR5: Controlling Target Engagement by Innovative Molecular Engineering



Dr Julie CHARTON
(UNIVERSITY OF LILLE, INSTITUT PASTEUR DE LILLE, Lille, France)

KL06 - Drug-target Residence Time – a Misleading Concept



Dr Rutger FOLMER
(SYMERES, Nijmegen, The Netherlands)

KL04 - Inducible Chemical-genetic Fluorescent Markers for Bioimaging

Confirmed Speakers



Dr Arnaud GAUTIER
(ECOLE NORMALE SUPÉRIEURE, Paris, France)

KL02 - Discovery of New Brain Penetrating Neuropeptide S Receptor (NPSR) Antagonists



Dr Julien POTHIER
(IDORSIA PHARMACEUTICALS LTD., Allschwil, Switzerland)

KL01 - Discovery of The Clinical Candidate Ribuvaptan, a Dual Acting Vasopressin V1a/V2 Receptor Antagonist for the Treatment of Heart Failure



Dr Carsten SCHMECK
(BAYER, Wuppertal, Germany)

KL03 - Dye-loaded Lipid Nanoparticles: Contrast Agents for Image-guided Surgery and Tools for Drug Delivery



Dr Isabelle TEXIER
(LETI-HEALTH, Grenoble, France)